Men’s experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study

• Published in: Cancer causes & control 2021-03, Vol.32 (3), p.261-269
• Main Authors: Sutton, E., Lane, J. A., Davis, M., Walsh, E. I., Neal, D. E., Hamdy, F. C., Mason, M., Staffurth, J., Martin, R. M., Metcalfe, C., Peters, T. J., Donovan, J. L., Wade, J.
• Format: Article
• Language: English
• Subjects: Age; Aged; Androgen Antagonists - adverse effects; Androgen Antagonists - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer Research; Combined Modality Therapy - adverse effects; Deprivation; Epidemiology; Hematology; Humans; Intestine; Longitudinal Studies; Male; Middle Aged; Normalizing; Oncology; Original Paper; Prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - radiotherapy; Public Health; Qualitative Research; Radiation Injuries - epidemiology; Radiation Injuries - etiology; Radiation therapy; Schedules; Side effects; Surveys and Questionnaires; Well being
• ISSN: 0957-5243; 1573-7225
• DOI: 10.1007/s10552-020-01380-3

Purpose To investigate men’s experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. Methods A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical characteristics. They participated in serial in-depth qualitative interviews for up to 8 years post-treatment, exploring experiences of treatment and its side effects over time. Results Men experienced bowel, sexual, and urinary side effects, mostly in the short term but some persisted and were bothersome. Most men downplayed the impacts, voicing expectations of age-related decline, and normalizing these changes. There was some reticence to seek help, with men prioritizing their relationships and overall health and well-being over returning to pretreatment levels of function. Some unmet needs with regard to information about treatment schedules and side effects were reported, particularly among men with continuing functional symptoms. Conclusions These findings reinforce the importance of providing universal clear, concise, and timely information and supportive resources in the short term, and more targeted and detailed information and care in the longer term to maintain and improve treatment experiences for men undergoing EBRT.